

Odd Terje Brustugun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4862995/publications.pdf>

Version: 2024-02-01

75
papers

2,714
citations

236925

25
h-index

197818

49
g-index

78
all docs

78
docs citations

78
times ranked

5320
citing authors

#	ARTICLE	IF	CITATIONS
1	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. <i>Nature Genetics</i> , 2017, 49, 65-74.	21.4	326
2	Stromal CD8+ T-cell Densityâ€”A Promising Supplement to TNM Staging in Nonâ€”Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2635-2643.	7.0	269
3	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018, 9, 1048.	12.8	254
4	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	12.8	239
5	Immune Cell Composition in Human Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 3101.	4.8	202
6	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	1.1	186
7	Sex-specific trends in lung cancer incidence and survival: a population study of 40 118 cases. <i>Thorax</i> , 2011, 66, 301-307.	5.6	123
8	Genomeâ€”wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. <i>Molecular Oncology</i> , 2016, 10, 330-343.	4.6	81
9	High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 321-331.	10.7	74
10	BRAF-mutations in non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 84, 36-38.	2.0	70
11	Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. <i>Acta OncolÃ³gica</i> , 2018, 57, 1225-1231.	1.8	59
12	The immune microenvironment in nonâ€”small cell lung cancer is predictive of prognosis after surgery. <i>Molecular Oncology</i> , 2019, 13, 1166-1179.	4.6	57
13	EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery. <i>Journal of Thoracic Oncology</i> , 2011, 6, 947-950.	1.1	48
14	NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors. <i>Genes and Cancer</i> , 2017, 8, 497-504.	1.9	47
15	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). <i>Lung Cancer</i> , 2020, 143, 27-35.	2.0	42
16	Lung cancer treatment is influenced by income, education, age and place of residence in a country with universal health coverage. <i>International Journal of Cancer</i> , 2016, 138, 1350-1360.	5.1	41
17	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. <i>Nature Cancer</i> , 2021, 2, 1224-1242.	13.2	37
18	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. <i>Frontiers in Immunology</i> , 2021, 12, 764596.	4.8	31

#	ARTICLE	IF	CITATIONS
19	Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population-Based Study of 1686 Cases. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1858-1861.	1.1	30
20	Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016. <i>Lung Cancer</i> , 2018, 122, 138-145.	2.0	30
21	PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. <i>Lung Cancer</i> , 2017, 103, 52-57.	2.0	28
22	Hypoxia as a Cause of Treatment Failure in Non-Small Cell Carcinoma of the Lung. <i>Seminars in Radiation Oncology</i> , 2015, 25, 87-92.	2.2	27
23	Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease. <i>BMC Cancer</i> , 2018, 18, 739.	2.6	27
24	Rapid reduction in the incidence of cancer of unknown primary. A population-based study. <i>Acta Oncologica</i> , 2014, 53, 134-137.	1.8	26
25	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. <i>Clinical and Translational Immunology</i> , 2016, 5, e109.	3.8	26
26	Cause-specific death after surgical resection for early-stage non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 221-227.	1.4	22
27	Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway. <i>Cancer Epidemiology</i> , 2019, 61, 59-69.	1.9	22
28	Antibody combinations for optimized staining of macrophages in human lung tumours. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12889.	2.7	16
29	Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. <i>F1000Research</i> , 2016, 5, 38.	1.6	15
30	The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes. <i>BMC Cancer</i> , 2016, 16, 71.	2.6	14
31	Increase in curative treatment and survival of lung cancer in Norway 2001–2016. <i>European Journal of Epidemiology</i> , 2019, 34, 951-955.	5.7	12
32	Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015–2016. <i>BMC Cancer</i> , 2020, 20, 488.	2.6	12
33	Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC. <i>Molecular Oncology</i> , 2019, 13, 2604-2615.	4.6	11
34	Expression of Estrogen Receptor- β and Survival in Advanced-stage Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 2261-2269.	1.1	11
35	Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer. <i>Diagnostic Pathology</i> , 2016, 11, 50.	2.0	10
36	Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers. <i>Frontiers in Oncology</i> , 2021, 11, 674731.	2.8	10

#	ARTICLE	IF	CITATIONS
37	Societal cost of cancer in Norway –Results of taking a broader cost perspective. <i>Health Policy</i> , 2021, 125, 1100-1107.	3.0	10
38	The Prognostic Effect of KRAS Mutations in Non-Small Cell Lung Carcinoma Revisited: A Norwegian Multicentre Study. <i>Cancers</i> , 2021, 13, 4294.	3.7	10
39	EGFR mutation testing of lung cancer patients – Experiences from Vestfold Hospital Trust. <i>Acta OncolÅ³gica</i> , 2016, 55, 149-155.	1.8	9
40	Management of Progressive Pulmonary Nodules FoundÅduring and outside of CT Lung Cancer Screening Studies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1755-1765.	1.1	9
41	Implementation of lung cancer CT screening in the Nordic countries. <i>Acta OncolÅ³gica</i> , 2017, 56, 1249-1257.	1.8	9
42	Molecular characterisation of <scp><i>TP53</i></scp> mutated squamous cell carcinomas of the lung to identify putative targets for therapy. <i>International Journal of Cancer</i> , 2020, 147, 2957-2966.	5.1	8
43	Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study. <i>Acta OncolÅ³gica</i> , 2021, 60, 1250-1256.	1.8	8
44	NUT expression in primary lung tumours. <i>Diagnostic Pathology</i> , 2015, 10, 156.	2.0	7
45	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020, 5, e000567.	4.5	7
46	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 9-16.	2.0	7
47	Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 130-138.	1.2	6
48	Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 590755.	2.8	6
49	The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12893.	2.7	6
50	Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100165.	1.1	6
51	Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. <i>Acta OncolÅ³gica</i> , 2020, 59, 1051-1057.	1.8	5
52	Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100168.	1.7	5
53	Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9007-9007.	1.6	5
54	Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer – predictors of response and impact of previous radiotherapy. <i>Acta OncolÅ³gica</i> , 2021, 60, 149-156.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Phase- and gender-specific, lifetime, and future costs of cancer. <i>Medicine (United States)</i> , 2021, 100, e26523.	1.0	4
56	Compliance with recommended cancer patient pathway timeframes and choice of treatment differed by cancer type and place of residence among cancer patients in Norway in 2015–2016. <i>BMC Cancer</i> , 2022, 22, 220.	2.6	4
57	Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 1738.	2.4	4
58	Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3430.	3.7	4
59	Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors. <i>BMC Cancer</i> , 2021, 21, 1089.	2.6	3
60	Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 873532.	2.8	3
61	Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. <i>Acta Oncologica</i> , 2021, 60, 1565-1571.	1.8	2
62	Factors associated with delayed treatment initiation in an unselected cohort of patients with small-cell lung cancer.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100477.	1.7	2
63	Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21026-e21026.	1.6	2
64	Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study. <i>Future Oncology</i> , 2021, . .	2.4	2
65	Factors affecting outcome in resected EGFR-mutated lung cancer. <i>Acta Oncologica</i> , 2022, 61, 749-756.	1.8	2
66	Stratification in advanced non-small cell lung cancer: precision medicine in practice. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 279-287.	0.7	1
67	Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 22, e555-e562.	2.6	1
68	Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 49-57.	2.0	1
69	A NOTCH added to metabolomics. <i>British Journal of Cancer</i> , 2019, 121, 3-4.	6.4	0
70	Randomized phase II trial comparing two schedules of thoracic radiotherapy (TRT) in limited disease small-cell lung cancer (LD SCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7027-7027.	1.6	0
71	PIK3CA as a prognostic marker in non-small cell lung cancer of squamous cell carcinoma type.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8105-8105.	1.6	0
72	Mutations in NSCLC.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18516-e18516.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Long term effect of nivolumab in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21156-e21156.	1.6	0
74	Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2nd line osimertinib.. Journal of Clinical Oncology, 2019, 37, e20544-e20544.	1.6	0
75	Radiation pneumonitis (RP) after stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC): A prospective, observational study.. Journal of Clinical Oncology, 2020, 38, e21065-e21065.	1.6	0